Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent and selective CXCR2 antagonist (IC50 = 40 nM). Exhibits selectivity for CXCR2 over a panel of 49 other GPCRs. Orally bioavailable.
NVP CXCR2 20 is also offered as part of the Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Porter et al (2014) The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists. Bioorg.Med.Chem.Lett. 24 3285 PMID: 24974342
Keywords: NVP CXCR2 20, NVP CXCR2 20 supplier, NVPCXCR220, chemokine, cxc, receptors, antagonists, antagonism, orally, bioavailable, potent, selective, Chemokine, CXC, Receptors, 5660, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for NVP CXCR2 20.
There are currently no reviews for this product. Be the first to review NVP CXCR2 20 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.